RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor. Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem. RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.
Location: Australia
Employees: 1-10
Total raised: $18.93M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | IP Group A... | ipgroupanz... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.11.2025 | Series A | $18.93M | IP Group |
Mentions in press and media 3
| Date | Title | Description |
| 15.11.2025 | Rage Biotech: Monash University Spin-Off Raises A$29 Million Series A To Advance RNA Therapeutics Toward Clinical Trials | RAGE Biotech, a Monash University spin-off, has secured A$29 million in Series A financing to accelerate the development of its next-generation RNA-based therapeutics for the treatment of chronic inflammatory diseases. The investment repres... |
| 18.04.2024 | Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" | MELBOURNE, Australia, April 18, 2024 /PRNewswire/ -- Australia's newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited ... |
| - | RAGE Biotech | “Rage Bio” |